FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy.

ABSTRACT: Chimeric antigen receptor (CAR) T cell therapy has transformed the treatment of haematological malignancies such as acute lymphoblastic leukaemia, B cell lymphoma and multiple myeloma^1-4, but the efficacy of CAR T cell therapy in solid tumours has been limited⁵. This is owing to a number of factors, including the immunosuppressive tumour microenvironment that gives rise to poorly persisting and metabolically dysfunctional T cells. Analysis of anti-CD19 CAR T cells used clinically has shown that positive treatment outcomes are associated with a more 'stem-like' phenotype and increased mitochondrial mass^6-8. We therefore sought to identify transcription factors that could enhance CAR T cell fitness and efficacy against solid tumours. Here we show that overexp

SUBMITTER: Chan JD 

PROVIDER: S-EPMC11062918 | biostudies-literature | 2024 May

REPOSITORIES: biostudies-literature